Organon & Co. Reports Q2 2026 Supplemental Financial Results: Key Non-GAAP Highlights and Shareholder Considerations
Organon & Co. has released supplemental financial information for the quarter and six months ended June 30, 2026, via an 8-K filing. The company emphasizes the use of non-GAAP financial measures to provide greater insight into its underlying business performance. These metrics are presented as a supplement to, not a replacement for, GAAP results.
Key Financial Highlights
-
GAAP vs. Non-GAAP Performance:
- Gross Profit (Q2 2026): \$847 million (GAAP) vs. \$915 million (Non-GAAP)
- Gross Margin (Q2 2026): 54.4% (GAAP) vs. 58.7% (Non-GAAP)
- Net Income (Q2 2026): \$108 million (GAAP) vs. \$230 million (Non-GAAP)
- Diluted EPS (Q2 2026): \$0.40 (GAAP) vs. \$0.85 (Non-GAAP)
- Adjusted EBITDA (Q2 2026): \$461 million
- Adjusted EBITDA margin (Q2 2026): 29.6%
-
Six-Month Results (YTD 2026):
- Gross Profit: \$1.63 billion (GAAP) vs. \$1.776 billion (Non-GAAP)
- Gross Margin: 54.0% (GAAP) vs. 58.8% (Non-GAAP)
- Net Income: \$254 million (GAAP) vs. \$418 million (Non-GAAP)
- Diluted EPS: \$0.95 (GAAP) vs. \$1.57 (Non-GAAP)
- Adjusted EBITDA: \$876 million
- Adjusted EBITDA Margin: 29.0%
Key Adjustments and Exclusions
- Manufacturing Network Costs: These include costs associated with exiting manufacturing and supply agreements with Merck & Co. and involve accelerated depreciation, exit premiums, and other transition-related expenses.
- Stock-Based Compensation: Excluded from adjusted metrics to better reflect operating performance.
- Amortization & Acquisition-Related Costs: Adjustments for amortization, especially related to the Dermavant Sciences transaction, and other acquisition-related impacts.
- Restructuring Charges: Significant restructuring costs, including those related to the company’s ongoing separation and transformation, have been adjusted out of Non-GAAP results.
- Jada Divestiture: For the six months ended June 30, 2026, a negative adjustment of \$81 million was made due to the divestiture of Jada, which may be of particular interest to shareholders.
- Other Notable Adjustments: Includes changes in the fair value of contingent consideration, and other expense/gain adjustments such as \$11 million in costs related to the pending transaction with Sun Pharmaceutical Industries Limited.
Noteworthy Items for Shareholders
- Margin Compression vs. Prior Year: Both GAAP and Non-GAAP gross margins as well as EBITDA margins are lower compared to the same period in 2025, indicating potential margin pressure.
- Higher Interest Expense: Interest expense remains elevated (\$108 million in Q2 2026), which could affect future earnings and cash flows.
- Tax Rate Differences: The GAAP effective tax rate is significantly higher than the Non-GAAP tax rate, which impacts reported net income and EPS. For Q2 2026, the GAAP tax rate was 41.3% vs. 28.8% Non-GAAP.
- Pending Sun Pharma Transaction: The company has incurred \$11 million in transaction costs related to a pending deal with Sun Pharmaceutical Industries Limited. Shareholders should monitor this closely as any material development could impact share value.
- Restructuring and Separation Costs: Ongoing adjustments for restructuring and costs related to the company’s separation from Merck & Co. remain a significant factor in the financials and could continue to affect results.
- Earnings Volatility Due to Adjustments: The substantial difference between GAAP and Non-GAAP earnings (e.g., Q2 2026 GAAP EPS \$0.40 vs. Non-GAAP \$0.85) highlights the importance of understanding the nature of these recurring adjustments.
Potential Price-Sensitive Developments
- Pursuit of Strategic Transactions: The costs associated with the Sun Pharma transaction indicate ongoing M&A activity. Any announcement regarding the closing, terms, or outcome of this transaction could significantly move the share price.
- Margin Trends: Investors should note the year-over-year decline in margins, which could affect market sentiment and valuations.
- Jada Divestiture Impact: The negative adjustment from the Jada divestiture is material and could influence investor perception of the company’s future growth prospects.
- Continued Transformation and Restructuring: The company’s ongoing transformation, restructuring, and separation activities are affecting reported results and may lead to further volatility.
Conclusion
Organon & Co.’s Q2 2026 supplemental financial information reveals a company in the midst of significant transformation. While Non-GAAP results portray underlying strength, the gap between adjusted and GAAP figures, ongoing restructuring, and pending transactions (notably with Sun Pharmaceutical) are critical for investors to watch. These factors could lead to further share price volatility depending on how they unfold in the coming quarters.
Disclaimer: This article is for informational purposes only and is not intended as investment advice. Investors should review the full financial filings and consult with a financial advisor before making investment decisions.
